Exchange: NASDAQ·Updated 04:10 PM EDT
PTGX logo

PTGX Protagonist Therapeutics Inc

$151.50
$0.91
(0.60%)
Today
Closed $151.50
$0.00
(0.00%)
After Hours
Reported EarningsAug 5
Mkt Cap$9.74B
Vol335,461.00

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
46

Neutral Sentiment

How do you feel about PTGX?

Advertisement|Remove ads.